PE20061367A1 - Nuevos derivados del fluoreno y composiciones que los contienen - Google Patents
Nuevos derivados del fluoreno y composiciones que los contienenInfo
- Publication number
- PE20061367A1 PE20061367A1 PE2006000520A PE2006000520A PE20061367A1 PE 20061367 A1 PE20061367 A1 PE 20061367A1 PE 2006000520 A PE2006000520 A PE 2006000520A PE 2006000520 A PE2006000520 A PE 2006000520A PE 20061367 A1 PE20061367 A1 PE 20061367A1
- Authority
- PE
- Peru
- Prior art keywords
- fluoren
- fluorine
- compositions containing
- new derivatives
- ona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A1, A2, A3 Y A4 SON DE PREFERENCIA CADA UNO, IGUALES O DIFERENTES CH2, N; (R2)p Y (R'2)p' SON DE PREFERENCIA H; R1 Y R1' IDENTICOS O DIFERENTES SON TALES QUE UNO DE R1 Y R1' ES H, HALOGENO, ALQUILO C1-C3, ALCOXI C1-C3, ENTRE OTROS Y EL OTRO DE R1 Y R1' ES H, HALOGENO, CF3, HIDROXILO, MERCAPTO, NITRO, AMINO, ENTRE OTROS O BIEN R1 Y R1' FORMAN JUNTO CON LOS ATOMOS DE CARBONO A LOS CUALES ESTAN UNIDOS UN RADICAL =O, =S, =N-NH2, =CH-OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(3H-IMADAZO[4,5-c]PIRIDIN-2-IL)-FLUOREN-9-ONA; 4-(6-FLUORO-1H-BENCIMIDAZOL-2-IL)-FLUOREN-9-ONA-OXIMA; 3,5-DIHIDROXI-N-[4-(3H-IMIDAZO[4,5-c]PIRIDIN-2-IL)-9H-FLUOREN-9(R,S)-IL]-BENZAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA CHAPERONA Hsp90 UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0505037A FR2885904B1 (fr) | 2005-05-19 | 2005-05-19 | Nouveaux derives du fluorene, compositions les contenant et utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061367A1 true PE20061367A1 (es) | 2007-01-08 |
Family
ID=36036699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000520A PE20061367A1 (es) | 2005-05-19 | 2006-05-17 | Nuevos derivados del fluoreno y composiciones que los contienen |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7674795B2 (es) |
| EP (1) | EP1888579B1 (es) |
| JP (1) | JP4964874B2 (es) |
| KR (1) | KR101288696B1 (es) |
| CN (1) | CN101203518B (es) |
| AR (1) | AR054125A1 (es) |
| AT (1) | ATE518859T1 (es) |
| AU (1) | AU2006248825B2 (es) |
| BR (1) | BRPI0611424A2 (es) |
| CA (1) | CA2608378C (es) |
| CR (1) | CR9515A (es) |
| DO (1) | DOP2006000112A (es) |
| EA (1) | EA019027B1 (es) |
| FR (1) | FR2885904B1 (es) |
| GT (1) | GT200600206A (es) |
| HN (1) | HN2006018410A (es) |
| IL (1) | IL187163A (es) |
| JO (1) | JO2753B1 (es) |
| MA (1) | MA29493B1 (es) |
| MX (1) | MX2007014443A (es) |
| MY (1) | MY149037A (es) |
| NO (1) | NO20076460L (es) |
| NZ (1) | NZ563239A (es) |
| PA (1) | PA8675701A1 (es) |
| PE (1) | PE20061367A1 (es) |
| TN (1) | TNSN07389A1 (es) |
| TW (1) | TWI386406B (es) |
| UA (1) | UA93203C2 (es) |
| UY (1) | UY29549A1 (es) |
| WO (1) | WO2006123061A2 (es) |
| ZA (1) | ZA200709856B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| FR2907453B1 (fr) * | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| WO2009066779A1 (ja) * | 2007-11-22 | 2009-05-28 | Idemitsu Kosan Co., Ltd. | 有機ｅｌ素子 |
| CN102046598B (zh) * | 2008-03-31 | 2015-02-04 | 科学与工业研究委员会 | 给体-受体芴支架:其方法和用途 |
| GB0809314D0 (en) * | 2008-05-22 | 2008-07-02 | Summit Corp Plc | Compounds for treating muscular dystrophy |
| CA2763536C (en) | 2008-05-30 | 2017-05-09 | Marvin J. Miller | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
| FR2932484B1 (fr) * | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP3252032A1 (en) | 2008-07-02 | 2017-12-06 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
| AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CA2786319C (en) | 2010-01-06 | 2019-03-12 | British Columbia Cancer Agency Branch | Bisphenol derivatives and their use as androgen receptor activity modulators |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| WO2012145330A1 (en) * | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
| CN102442973A (zh) * | 2011-09-22 | 2012-05-09 | 华东理工大学 | 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法 |
| CN108148186A (zh) | 2012-01-31 | 2018-06-12 | 剑桥显示技术有限公司 | 聚合物 |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| SG11201407775WA (en) | 2012-05-25 | 2014-12-30 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
| EP3348545A1 (en) | 2013-03-15 | 2018-07-18 | Japan Tobacco Inc. | Pyrazole-amide compound and medicinal uses therefor |
| CN105358522A (zh) | 2013-05-10 | 2016-02-24 | 不列颠哥伦比亚癌症局分支机构 | 雄激素受体调节剂的酯衍生物及其使用方法 |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR20160054523A (ko) | 2013-09-09 | 2016-05-16 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | 암 영상화 및 치료용 할로겐화 화합물, 및 이들의 사용 방법 |
| KR102280686B1 (ko) | 2014-02-11 | 2021-07-22 | 삼성전자주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| WO2016090373A1 (en) | 2014-12-05 | 2016-06-09 | Case Western Reserve University | Compositions and methods of modulating s-nitrosylation |
| US11426386B2 (en) | 2014-12-05 | 2022-08-30 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
| ES2907708T3 (es) | 2015-01-13 | 2022-04-26 | British Columbia Cancer Agency Branch | Compuestos heterocíclicos para obtención de imágenes y tratamiento del cáncer y métodos para su uso |
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| WO2016197032A1 (en) * | 2015-06-04 | 2016-12-08 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| JP7036724B2 (ja) | 2016-07-29 | 2022-03-15 | 日本たばこ産業株式会社 | ピラゾール－アミド化合物の製造方法 |
| US11576900B2 (en) | 2017-09-25 | 2023-02-14 | Case Western Reserve University | Compositions and methods of reducing serum cholesterol and PCSK9 |
| US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| WO2020005938A1 (en) | 2018-06-25 | 2020-01-02 | Case Western Reserve University | Compositions and methods for treating tissue injury |
| CN113038947A (zh) * | 2018-09-21 | 2021-06-25 | 卡斯西部储备大学 | 醛酮还原酶抑制剂及其用途 |
| WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| CN109574917B (zh) * | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| CA3125350A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
| CN110981795B (zh) * | 2019-12-18 | 2021-02-12 | 武汉世纪久海检测技术有限公司 | 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法 |
| US20210323931A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6015796A (en) * | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| AU2001286454B2 (en) * | 2000-08-14 | 2006-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
| EP1456180B1 (en) * | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use |
| GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| EP1572682A4 (en) * | 2002-12-20 | 2008-01-23 | Pharmacia Corp | ACYCLIC PYRAZOLE COMPOUNDS |
| WO2004072080A1 (en) * | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
| JP4921162B2 (ja) | 2003-02-11 | 2012-04-25 | ヴァーナリス（ケンブリッジ）リミテッド | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
| GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
| CA2530374C (en) | 2003-06-27 | 2012-05-15 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| EP1675861B1 (en) | 2003-08-29 | 2015-12-23 | Vernalis (R&D) Ltd. | Pyrimidothiophene compounds |
| GB0323810D0 (en) * | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
| WO2005063222A1 (ja) * | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| FR2884252B1 (fr) * | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
-
2005
- 2005-05-19 FR FR0505037A patent/FR2885904B1/fr not_active Expired - Fee Related
-
2006
- 2006-05-12 DO DO2006000112A patent/DOP2006000112A/es unknown
- 2006-05-14 JO JO2006135A patent/JO2753B1/en active
- 2006-05-17 AR ARP060101980A patent/AR054125A1/es not_active Application Discontinuation
- 2006-05-17 HN HN2006018410A patent/HN2006018410A/es unknown
- 2006-05-17 PE PE2006000520A patent/PE20061367A1/es not_active Application Discontinuation
- 2006-05-18 PA PA20068675701A patent/PA8675701A1/es unknown
- 2006-05-18 MY MYPI20062304A patent/MY149037A/en unknown
- 2006-05-18 GT GT200600206A patent/GT200600206A/es unknown
- 2006-05-19 EA EA200702531A patent/EA019027B1/ru unknown
- 2006-05-19 AT AT06755509T patent/ATE518859T1/de not_active IP Right Cessation
- 2006-05-19 JP JP2008511754A patent/JP4964874B2/ja not_active Expired - Fee Related
- 2006-05-19 TW TW095117762A patent/TWI386406B/zh not_active IP Right Cessation
- 2006-05-19 KR KR1020077029644A patent/KR101288696B1/ko not_active IP Right Cessation
- 2006-05-19 CN CN2006800219737A patent/CN101203518B/zh not_active Expired - Fee Related
- 2006-05-19 UA UAA200714230A patent/UA93203C2/ru unknown
- 2006-05-19 AU AU2006248825A patent/AU2006248825B2/en not_active Ceased
- 2006-05-19 NZ NZ563239A patent/NZ563239A/en not_active IP Right Cessation
- 2006-05-19 CA CA2608378A patent/CA2608378C/fr not_active Expired - Fee Related
- 2006-05-19 WO PCT/FR2006/001137 patent/WO2006123061A2/fr not_active Application Discontinuation
- 2006-05-19 EP EP06755509A patent/EP1888579B1/fr active Active
- 2006-05-19 BR BRPI0611424-5A patent/BRPI0611424A2/pt not_active IP Right Cessation
- 2006-05-19 UY UY29549A patent/UY29549A1/es unknown
- 2006-05-19 MX MX2007014443A patent/MX2007014443A/es active IP Right Grant
-
2007
- 2007-10-18 TN TNP2007000389A patent/TNSN07389A1/en unknown
- 2007-11-05 IL IL187163A patent/IL187163A/en not_active IP Right Cessation
- 2007-11-13 CR CR9515A patent/CR9515A/es unknown
- 2007-11-14 US US11/939,735 patent/US7674795B2/en active Active
- 2007-11-15 ZA ZA2007/09856A patent/ZA200709856B/en unknown
- 2007-11-29 MA MA30431A patent/MA29493B1/fr unknown
- 2007-12-14 NO NO20076460A patent/NO20076460L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061367A1 (es) | Nuevos derivados del fluoreno y composiciones que los contienen | |
| PE20211411A1 (es) | Compuestos de anillo fusionado | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| LTPA2016016I1 (lt) | Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui | |
| CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
| EA200400073A1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
| CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| EA200700099A1 (ru) | Производные пиридина | |
| EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| UY29246A1 (es) | Nuevos compuestos | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| PE20120798A1 (es) | Potentes inhibidores de molecula pequena de autofagia | |
| EA200702498A1 (ru) | N-(пиридин-2-ил)сульфонамидные производные | |
| CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
| DK1392714T3 (da) | Steroider som agonister for FXR | |
| PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| CY1109775T1 (el) | Κρυσταλλικες μορφες μιας διφαινυλικης ενωσης | |
| EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
| AR054688A1 (es) | Alquil-piridinas como inhibidores 11-beta de la diabetes | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
| PE20071089A1 (es) | Compuesto heterociclico fusionado como inhibidor de tirosina quinasa | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |